Clinical trials
Macular Degeneration clinical trials
Below are recruiting macular degeneration clinical trials, each written for real people, not researchers. We’re tracking 168 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07135570Recruiting
My Eyes, My Light: Amar Chokh, Amar Alo
This trial is studying people living in Char Fasson, Bangladesh, to see who might have undiagnosed eye problems. It's a local screening program to catch eye issues early.
Char Fasson, BholaAges 35 years+ - NCT07158775RecruitingPhase 1/Phase 2
BS01 gene therapy for dry age-related macular degeneration
This trial tests a new gene therapy, BS01, given as an eye injection. It is for people with advanced dry age-related macular degeneration (AMD) that has caused geographic atrophy—damage to the central part of the retina. The study aims to see if the treatment is safe and can help slow vision loss.
Edison, New JerseyAges 50–85 - NCT07164378Recruiting
Study of an implant for vision loss from advanced AMD
This trial tests a small telescope implant for people with advanced age-related macular degeneration (AMD) in both eyes. It aims to improve central vision in the eye where the implant is placed.
MarseilleAges 55 years+ - NCT07215234RecruitingPhase 1/Phase 2
Study of an injection for geographic atrophy in AMD
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
Peoria, ArizonaAges 60 years+ - NCT01866371Recruiting
High-detail eye scans for children and adults
This study tests a high-resolution imaging method that takes very detailed pictures of the retina (the light-sensing layer at the back of the eye). You might benefit by getting your eye health checked in a structured imaging study—if you’re able to comfortably complete the scan.
Philadelphia, PennsylvaniaAges 7 years+ - NCT02026843Recruiting
Testing eye fluid markers in chorioretinal eye diseases
This study looks at substances (“biomarkers”) in the clear fluid inside the eye to better understand several eye conditions that affect vision. Your results may help doctors learn how these diseases work and how treatments might be chosen.
Daegu, KyungsangpookdoAges 20–80 - NCT01496625Recruiting
Biobank study for retinal diseases and comparison samples
This study collects and stores blood and eye-related medical information to help researchers better understand retinal diseases, including age-related macular degeneration and diabetic retinopathy. Your samples may also be used to compare people with retinal disease to people without it.
Bethesda, MarylandAges 2–120 - NCT02435940Recruiting
Registry for inherited eye vision conditions
This study is a registry, meaning it collects information about people with inherited retinal (retina) diseases. It may help researchers learn how these conditions progress and connect you with future studies or treatments.
Columbia, MarylandAges Any age - NCT02253030Recruiting
Eye scan study for newly diagnosed wet AMD
This study uses a special eye scan (OCT angiography) to look at new, abnormal blood vessel growth in people with wet age-related macular degeneration (wet AMD) who have not been treated yet. It may help researchers better understand the disease and how it changes over time.
Portland, OregonAges 50–100 - NCT07403825RecruitingPhase 4
Faricimab for wet AMD with subretinal material
This trial tests a new drug called Faricimab for people with a specific type of wet age-related macular degeneration (AMD) that has a buildup of material beneath the retina. The goal is to see if Faricimab can help clear this material and improve vision.
Córdoba, AndalusiaAges 50 years+ - NCT07446582Recruiting
AI camera test for wet AMD detection
This study tests a new AI-powered camera that takes special pictures of the back of the eye to find signs of wet age-related macular degeneration (AMD) more easily. It compares images from people with wet AMD and healthy volunteers to see if the AI can spot the disease early.
Woodbridge, New JerseyAges 40 years+ - NCT07461441RecruitingPhase 3
Personalized faricimab for new polypoidal choroidal vasculopathy
This study tests a personalized treatment plan using an investigational drug called faricimab for people who have a specific type of wet age-related macular degeneration known as polypoidal choroidal vasculopathy. The goal is to see if adjusting the time between injections based on your individual needs can safely dry up fluid in the retina and improve vision.
Daegu, NamguAges 50 years+ - NCT07515521Recruiting
Vision and Imaging Tests for Early and Intermediate AMD
This study tests new ways to measure vision and take detailed eye images in people with age-related macular degeneration (AMD), a common eye condition affecting central vision. The goal is to develop better tools for future AMD treatment trials.
BonnAges 18 years+ - NCT07531927Recruiting
Electrical Stimulation for Geographic Atrophy Vision Loss
This study tests whether gentle electrical stimulation applied to the eye can help slow vision loss from geographic atrophy, a common cause of blindness in older adults. The treatment uses a special device to stimulate the retina (the light-sensing tissue in the back of your eye).
HamburgAges 60 years+ - NCT07550777Recruiting
Heart Health and Eye Injections Study
This study looks at how repeated eye injections of a drug called bevacizumab affect chemicals in your blood that relate to heart health and inflammation. Researchers want to understand if these eye injections might impact your cardiovascular risk.
Erzurum, ErzurumAges 50–80 - NCT07555574Recruiting
New imaging technology to see retinal structures clearly
This research study tests a new camera technology that takes detailed pictures of the back of your eye (retina) to better understand eye diseases. Researchers want to compare images from people with eye conditions like diabetes-related eye disease, glaucoma, or age-related macular degeneration with healthy volunteers to see how the new imaging works.
Melbourne, VictoriaAges 18 years+ - NCT07556406Recruiting
Eye imaging study for age-related macular degeneration
This study uses specialized eye imaging to track changes in geographic atrophy, a type of vision loss from macular degeneration. Researchers will use new imaging techniques to better understand how this condition progresses and how treatments work.
San Francisco, CaliforniaAges 55 years+ - NCT07577219Recruiting
Vision Training With Feedback for Central Vision Loss
This study teaches people with central vision loss (blurred or missing spots in the middle of vision) how to use their remaining side vision better, using special training with audio and visual feedback. It may help improve how well you can read and recognize faces.
Boston, MassachusettsAges 14 years+ - NCT07653269Recruiting
Tracking eye changes to predict AMD progression
This study uses eye imaging and other tests to predict if early age-related macular degeneration (AMD) will progress to a more advanced stage. It aims to help doctors identify who might need closer monitoring in the future.
SingaporeAges 55 years+ - NCT07668804RecruitingPhase 1/Phase 2
Study of an eye implant for geographic atrophy from dry AMD
This trial is testing a new eye implant (TO-O-1007) to see if it's safe and helps slow vision loss from geographic atrophy, a late stage of dry age-related macular degeneration (AMD). The implant is placed inside the eye and releases medicine over time.
Hurstville, New South Wales (nsw)Ages 50 years+ - NCT06737354Enrolling by invitationPhase 1
Study of IVB103 injection for wet age-related macular degeneration
This trial tests a new treatment called IVB103 for people with wet age-related macular degeneration (AMD). It aims to see if the injection is safe and effective for those who have already had anti-VEGF therapy. You may qualify if you have active disease and have had at least two prior anti-VEGF treatments.
Chengdu, SichuanAges 50 years+ - NCT06682455Enrolling by invitation
Predicting AMD progression with advanced scans and AI
This study is looking at people with intermediate AMD who previously took part in the PINNACLE study. It will use advanced eye scans and machine learning to learn more about how AMD progresses and how to predict it.
ViennaAges Any age - NCT06583395Enrolling by invitation
Meditation retreat study with fitness tracker
This trial studies people attending a 7-day meditation retreat to see how meditation affects well-being. You will wear a fitness tracker and answer surveys.
Palm Desert, CaliforniaAges 21 years+ - NCT04129021Recruiting
Eye imaging test with fast detailed scans
This trial studies whether a new, very high-resolution and high-speed eye scan can be used for people with eye problems or for healthy volunteers. It may help doctors better “see” eye structures more clearly to guide care.
ParisAges 18 years+
Hear when a new Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for macular degeneration?
- Yes. Clin2 currently lists 168 recruiting macular degeneration studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a macular degeneration trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a macular degeneration trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Age-Related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Neovascular Age-Related Macular Degeneration (nAMD)
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- Neovascular (Wet) Age-Related Macular Degeneration
- Age-related Macular Degeneration (ARMD)
- Exudative Age-Related Macular Degeneration
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.